SNO 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Jazz Pharmaceuticals at SNO 2026

Nov 12–15, 2026 Philadelphia, PA ~3k attendees Website

Jazz Pharmaceuticals brings 5 presentations to SNO 2026 in Philadelphia. Its program focuses on H3 K27M-mutant diffuse glioma, with industry-supported sessions on diagnosis and treatment. Research on its ClpP agonist in a phase 2 study also features.

OrganizationSNO 2026 Attendance
Jazz Pharmaceuticals
Dublin, Ireland
◆Platinum Supporter
Large pharmaPlatinum Supporter
A biopharmaceutical company developing and marketing medicines, including therapies used in neuro-oncology.
Talk
Fri Nov 13
7–8:15am
Implementing Systemic Therapy in H3 K27-Altered DMG: Practical Strategies to Optimize Post-Radiation Care
Independence Ballroom, Level 3, Philadelphia Marriott Downtown
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
A phase 2 study to investigate the efficacy and safety of JZP3507 (formerly ONC206) in adults with recurrent grade 2 or 3 meningioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TIP-12
Trials
Talk
Sat Nov 14
7–8:15am
Advances in Diagnosis and Treatment of H3 K27M-Mutant Diffuse Glioma
Liberty Ballroom ABC - Philadelphia Marriott Downtown
Therapeutics
Talk
Sat Nov 14
3:19–3:24pm
Session
Sat Nov 14
6–7pm

Explore the full SNO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Philadelphia. Leave your work email and we’ll be in touch.

Privacy

Download the full SNO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Jazz Pharmaceuticals

Tell us what you sell and we’ll find the people at Jazz Pharmaceuticals most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the Society for Neuro-Oncology. Submit a correction